Brokers Offer Predictions for MiMedx Group FY2025 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for MiMedx Group in a research report issued on Friday, May 2nd. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings per share of $0.24 for the year, down from their previous forecast of $0.30. Cantor Fitzgerald currently has a "Overweight" rating and a $13.00 price target on the stock. The consensus estimate for MiMedx Group's current full-year earnings is $0.30 per share.

Separately, StockNews.com raised MiMedx Group from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 1st.

MiMedx Group Stock Down 0.2 %

NASDAQ:MDXG traded down $0.01 during mid-day trading on Monday, hitting $6.61. 1,536,034 shares of the company's stock were exchanged, compared to its average volume of 685,787. The company has a market cap of $976.31 million, a PE ratio of 12.02 and a beta of 1.85. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. MiMedx Group has a one year low of $5.47 and a one year high of $10.14. The business has a fifty day moving average price of $7.38 and a 200 day moving average price of $8.11.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. The business had revenue of $88.21 million for the quarter, compared to analysts' expectations of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%.

Institutional Investors Weigh In On MiMedx Group

Several hedge funds and other institutional investors have recently made changes to their positions in MDXG. IMG Wealth Management Inc. bought a new position in MiMedx Group in the fourth quarter worth approximately $28,000. Virtus Fund Advisers LLC bought a new position in shares of MiMedx Group in the fourth quarter worth about $35,000. Van ECK Associates Corp purchased a new position in shares of MiMedx Group during the 4th quarter valued at about $40,000. Tower Research Capital LLC TRC grew its stake in shares of MiMedx Group by 77.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after acquiring an additional 2,837 shares during the period. Finally, AlphaQuest LLC purchased a new stake in MiMedx Group in the 4th quarter worth approximately $88,000. Hedge funds and other institutional investors own 79.15% of the company's stock.

Insider Buying and Selling at MiMedx Group

In other news, CEO Joseph H. Capper acquired 200,000 shares of the business's stock in a transaction that occurred on Friday, May 2nd. The stock was bought at an average price of $6.34 per share, with a total value of $1,268,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 529,530 shares of the company's stock, valued at approximately $3,357,220.20. The trade was a 60.69 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO William Frank Iv Hulse sold 81,446 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the sale, the chief accounting officer now owns 494,774 shares of the company's stock, valued at approximately $3,859,237.20. This trade represents a 14.13 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 144,018 shares of company stock worth $1,130,312. Insiders own 1.30% of the company's stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.